Tekmira Pharmaceuticals Corporation Grants Alnylam a License to Use Tekmira's LNP Technology
receive milestones and royalties as Alnylam's LNP enabled products are developed and commercialized.
Tekmira will receive a $5 million payment related to initiation of clinical trials for ALN-VSP in China. Alnylam has guided that it expects to report results in mid-2013 from its Phase II study with ALN-TTR02 in patients with ATTR, and anticipates initiating a Phase III pivotal trial of ALN-TTR02 in late 2013. Tekmira will receive a $5 million milestone payment upon ALN-TTR02 entering a pivotal trial and royalties on commercial sales of ALN-TTR.